Market report: Healthcare index slips for the week as wider market holds on
15 October, 2010 by Staff WritersThe S&P/ASX 200 Healthcare Index fell for the week while the broader market just clung onto positive territory.
Resolving the controversy over anti-aging sirtuins
15 October, 2010 by Tim DeanThey hold the promise of not only treating manifold diseases, from Type 2 diabetes, to neurodegenerative, cardiovascular and inflammatory disease, but also of extending life and improving general health.
Opinion: Why Australia should be proud of its clinical trial industry
12 October, 2010 by Staff WritersPerhaps it was the very success of the CTN scheme in making Australia an attractive location for clinical research, and the corresponding increase in the number of studies conducted here, that has led to the perceived loss of international standing because of start-up delays and congestion in the Human Research Ethics Committee (HREC) system.
Market report: Healthcare index up as wider market falls
24 September, 2010 by David BinningIn a reversal of last week's pattern, the S&P ASX/200 Healthcare Index put on a strong showing today to finish the week in positive territory while the wider market fell to snap a three week winning streak.
J&J to buy Crucell for US$2.29 billion
21 September, 2010 by Staff WritersJohnson & Johnson has offered US$2.29 billion to buy Dutch biotech Crucell NV, the two companies announced this week.
Ability for introspection linked to brain biology
19 September, 2010 by Staff WritersBritish scientists believe they have found the biological explanation for why some people are better than others at the important facility of introspection.
Avita wins US defence contract
15 September, 2010 by David BinningAvita Medical has won a $US1.8 million contract with the US army to apply its ReCell spray-on skin technology on wounded personnel.
Universal Biosensors refuses to deny acquisition rumours
13 September, 2010 by David BinningResponding to reports in ALS last Friday that his company may be on the market, Univeral Biosensors chairman and interim CEO Andy Denver said today that “we are always up for sale”.
Novogen to sell isoflavone portfolio to Marshall Edwards
09 September, 2010 by David BinningAustralian drug development company Novogen announced today that it has agreed to sell the rights to its entire isoflavone portfolio to US subsidiary Marshall Edwards in return for stock.
New policy framework needed for medical research: Research Australia
08 September, 2010 by David BinningResearch Australia will next month to unveil a major new policy framework which it hopes will lead to more investment and greater collaboration around medical research in Australia.
Broadvector to raise $8.5m for prostate cancer and loose prosthetics
07 September, 2010 by David BinningAged health specialist Broadvector has issued a prospectus as it seeks to raise around $8.5 million to fund the development of a novel prostate cancer therapy in addition to a treatment addressing the problem of ascpetic loosening of hip replacements.
Market report: ASX posts strong week following robust economic data
03 September, 2010 by David BinningThe Australian Stock Market finished up for the week today, ending several weeks of losses, as investors warmed to the positive outlook for the local economy.
Halcygen reports maiden profit
01 September, 2010 by Staff WritersAntibiotic developer Halcygen Pharmaceuticals today reported a maiden net profit of $3.25 million for the year ended June 30, 2010, largely driven by the company’s acquisition of Mayne Pharma International late last year from Hospira Inc.
Market report: Healthcare index outperforms wider market
27 August, 2010 by David BinningThe Australian stock market just clawed its way into positive territory today as investors defied the prevailing gloom surrounding the US economy, although it wasn’t enough to snap a three-week losing streak.
China and India pharma companies driving M&A activity in Asia
27 August, 2010 by Staff WritersA report by analyst group Datamonitor has identified China and India’s pharmaceutical industries as the ones to watch following a flurry of M&A activity over the last three years.
